相关实验视频
Updated: Jul 11, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
445
针对肥胖的肠道激素的最新药理干预措施
Michael Camilleri1, Andres Acosta1
1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA.
British journal of pharmacology
|November 2, 2023
概括
较新的因克列受体激动剂为肥胖提供了有前途的药理疗法,影响食欲和胃排空以减肥. 未来的发展包括口服药物和三重激动剂,以加强代谢控制.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 肥胖问题研究研究
背景情况:
- 肥胖是一种复杂的代谢障碍,具有重大公共卫生影响.
- 药理干预对于管理肥胖及其伴随疾病至关重要.
- 基于因克雷的疗法已经成为肥胖治疗的重大进展.
研究的目的:
- 审查针对肥胖症的新型药理干预措施,重点关注因克列受体激动剂.
- 讨论正在开发的或已批准用于肥胖症的单,双和三重因克列受体激动剂.
- 为了检查这些药物对胃排空,食欲调节和减肥的影响.
主要方法:
- 对肥胖的已批准和管道中的药理学药物的文献综述.
- 分析胰岛素受体点:类似葡萄糖-1 (GLP-1),依赖葡萄糖的胰岛素 (GIP) 和葡萄糖.
- 检查对中央食欲控制和周边机制 (如胃空气) 的影响.
主要成果:
- 几种单和双激素激动剂 (例如,利拉格卢提德,塞马格卢提德) 已被批准用于皮下注射.
- 目前正在开发实验性双重和三重烯酸激动剂,氨酸类似物和PYY类似物.
- 口服塞马格卢提德已被批准用于2型糖尿病,并正在接受肥胖的审查;预计将有口服小分子GLP-1激动剂.
结论:
- 胰岛素受体激活剂代表了肥胖药物治疗的重大进步.
- 这些药物通过对食欲和胃空化的作用来证明有效性,有助于减肥.
- 未来的研究和开发重点是更强效和更方便的配方,包括口服药物和三重激动剂.
相关概念视频
Hormonal Regulation
43.5K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.5K
Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
Regulation of Food Intake
247
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
247
Regulation of the Digestive System
627
Digestive activity regulation hinges on three primary components. Activation is prompted by a multitude of mechanical and chemical indicators, primarily detected by receptors within the stomach and intestines' walls. These receptors predominantly respond to factors such as mechanical stretching of the organ walls, changes in pH and osmolarity, and the presence of digesting materials and their by-products.
The effectors in this regulation system are glands and smooth muscles. Activation of...
The effectors in this regulation system are glands and smooth muscles. Activation of...
627
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
183
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
270
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
270

